{
  "nctId": "NCT04509076",
  "briefTitle": "PrEP iT! Mobile App Intervention",
  "officialTitle": "PrEP iT!: A Pilot Test of a Mobile Peer Support Intervention to Optimize PrEP Adherence and Retention in PrEP Care",
  "protocolDocument": {
    "nctId": "NCT04509076",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2020-09-14",
    "uploadDate": "2023-04-26T14:56",
    "size": 611860,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04509076/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 80,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2021-03-01",
    "completionDate": "2022-04-15",
    "primaryCompletionDate": "2022-04-15",
    "firstSubmitDate": "2020-03-23",
    "firstPostDate": "2020-08-11"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion criteria for the pilot RCT are:\n\n1. Prescribed PrEP by a healthcare provider;\n2. Self-reported 18-29 years of age;\n3. Assigned male at birth;\n4. Current male gender identification;\n5. Gay, bisexual or other non-heterosexual identity or has had sex with a man in the past year;\n6. Confirmed HIV-negative status (before starting PrEP);\n7. Started PrEP in the past 6 months (either taking PrEP for the first time or restarting PrEP after prior use) and has a current PrEP prescription;\n8. English-speaking (as the intervention will be built in English);\n9. Able to meet with project staff at baseline and follow-up visits;\n10. Regular access to SMS or the internet, either through a mobile device, tablet computer, and/or desktop or laptop computer",
    "healthyVolunteers": true,
    "sex": "MALE",
    "minimumAge": "18 Years",
    "maximumAge": "29 Years",
    "stdAges": [
      "ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "High Protective Level of PrEP Adherence From Tenofovir Diphosphate (TVF-DP) Levels",
        "description": "Adherence thresholds estimated through analysis of tenofovir diphosphate (TVF-DP) levels from dried blood spot (DBS) specimens were used to categorize each participant as having a high protective level (i.e., a high likelihood of protection from HIV) of PrEP (800 or greater of emtricitabine-tenofovir disoproxil fumarate \\[FTC-TDF\\] and 950 or greater of FTC-tenofovir alafenamide \\[FTC-TAF\\]) or not. Results reported here are for high protective levels of PrEP.",
        "timeFrame": "6-month follow up assessment"
      },
      {
        "measure": "Proportion of Participants With High Self-reported PrEP Adherence in the Past 7 Days",
        "description": "Participants were asked at the month 6 survey to respond to the following item: \"In the past 7 days, how many days did you take PrEP?\" Response options ranging from 0 days to 7 days, with 1 day increments. Responses of 4, 5, 6, or 7 days were categorized as having a high protective level of PrEP (i.e., a high likelihood of protection from HIV). Results reported here are for high protective levels of PrEP.",
        "timeFrame": "6-month follow up assessment"
      }
    ],
    "secondary": [],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 0,
      "exclusionCount": 0,
      "totalCount": 0
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 0,
      "otherCount": 0,
      "totalCount": 2
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 30,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:30:18.858Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}